Loading...

Jennifer Clarke, MD, MPH

TitleAssociate Professor
SchoolUCSF School of Medicine
DepartmentNeurology
Address400 Parnassus Ave, UC Clinics
San Francisco CA 94158
Phone415-353-2383
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Clinical Trials
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke J, Pampaloni MH, Cha S. Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines. 2016 Oct 31; 4(4). PMID: 28536391.
      View in: PubMed
    2. Raleigh DR, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke J, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA, et al. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2016 Jun 9. PMID: 27282397.
      View in: PubMed
    3. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200. PMID: 26493740.
      View in: PubMed
    4. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53; discussion 253. PMID: 25856113; PMCID: PMC4506198.
    5. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5. PMID: 26181937.
      View in: PubMed
    6. Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol. 2015; 2015:731361. PMID: 25793136; PMCID: PMC4352456.
    7. Clarke JL. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma. Semin Radiat Oncol. 2014 Oct; 24(4):273-8. PMID: 25219812.
      View in: PubMed
    8. Fogh S, Wahl M, Anwar M, Haas-Kogan D, Clarke JL, Sneed PK. Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):259-64. PMID: 25219810.
      View in: PubMed
    9. Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40. PMID: 25208478.
      View in: PubMed
    10. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90. PMID: 24637230; PMCID: PMC4057142.
    11. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62. PMID: 24670608; PMCID: PMC4136897.
    12. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9. PMID: 24335700; PMCID: PMC3895386.
    13. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013 Jan; 15(1):91-6. PMID: 23095230; PMCID: PMC3534420.
    14. Nagpal S, Clarke JL. Neoplastic myelopathy. Semin Neurol. 2012 Apr; 32(2):137-45. PMID: 22961188.
      View in: PubMed
    15. Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 2012 Apr; 18(2):328-42. PMID: 22810130.
      View in: PubMed
    16. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70. PMID: 21841523.
      View in: PubMed
    17. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012 Feb; 7(2):382-5. PMID: 22089116.
      View in: PubMed
    18. Clarke JL, Deangelis LM. Primary central nervous system lymphoma. Handb Clin Neurol. 2012; 105:517-27. PMID: 22230516.
      View in: PubMed
    19. Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):26-31. PMID: 22290254.
      View in: PubMed
    20. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80. PMID: 21969507; PMCID: PMC3208537.
    21. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011 Dec; 13(12):1364-9. PMID: 21865399; PMCID: PMC3223088.
    22. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24. PMID: 21813511; PMCID: PMC3177665.
    23. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010 Sep; 99(2):283-6. PMID: 20146086; PMCID: PMC3973736.
    24. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82. PMID: 20167815; PMCID: PMC2940590.
    25. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 Aug 10; 27(23):3861-7. PMID: 19506159; PMCID: PMC2727290.
    26. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009 May; 9(3):241-6. PMID: 19348713.
      View in: PubMed
    27. Clarke JL, Johnston SC, Farrant M, Bernstein R, Tong D, Hemphill JC. External validation of the ICH score. Neurocrit Care. 2004; 1(1):53-60. PMID: 16174898.
      View in: PubMed
    Jennifer's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP